NCT05666453终止2 期
A Multi-center, Prospective, Randomized, Controlled, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin to Prevent Biliary Complications After ABO Incompatible Adult to Adult Living Donor Liver Transplantation
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 59
- 试验地点
- 5
- 主要终点
- Rate of biliary complications
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of LIV-GAMMA SN Inj. administered for consecutive 3 days in adult subjects to prevent biliary complications after ABO incompatible adult to adult living donor liver transplantation (LDLT). The primary objective of this study is to determine the incidence rate of biliary complications for 48 weeks after liver transplantation. Incidence rate of transplant rejection, DSA, antibody reaction, CMV infection, infectious complications, DIHBS and recurrence rate of HCC as well as adverse events are assessed as additional efficacy and safety endpoints in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed informed consent process
- •Male or female aged ≥19 years and <75 years
- •Patients scheduled hospitalization for liver transplantation
排除标准
- •Patients who are scheduled or have history of re-transplantation or multiorgan transplantation
- •Patients receiving living donor in emergency
- •Patients with Donor Specific Antibody (DSA) ≥ MFI 10,000 or Human Leukocyte Antigen (HLA) crossmatch (+) cytotoxic T-cell ≥ 1:32
- •Patients with a history of biliary tract disease
- •Patients who plasma exchange is forbidden (with a history of allergic or anaphylactic reaction to FFP, albumin, heparin, etc.)
- •Patients with a history of specific medical conditions
- •Severe renal failure (eGFR < 30 mL/min/1.73 m^2 at screening)
- •Deep Vein Thrombosis (DVT) or thrombotic complications from Intravenous Immunoglobulin (IVIg) therapy
- •Cerebrovascular or cardiovascular disease (Hyperviscosity syndrome, Transient Ischemic Attack (TIA), Stroke, Thromboembolism, Unstable angina, etc.)
- •Clinical state causing secondary immunodeficiency (Leukemia, Lymphoma, Multiple myeloma, HIV infection, Chronic or Cyclic neutropenia (Absolute neutrophil < 500/mm^3), etc.)
- •Uncontrolled hypertension (Systolic blood pressure > 160 mmHg or Diastolic blood pressure > 100 mmHg)
- •Hemolytic or hemorrhagic anemia
- •Decreased cardiac functions
- •Bacterial, fungal or viral infection making liver transplantation forbidden
- •Intraductal or vascular infiltration observed in patients with hepatocellular carcinoma using medical imaging before liver transplantation
- •Patients metastasized to organs except for liver or diagnosed cancer except for liver cancer and squamous cell carcinoma within 5 years from screening
- •Patients with sepsis
- •Patients who had interventional therapy in blood vessels (hepatic vein, portal vein, hepatic artery, etc.) or bile ducts before LDLT
- •Patients who have allergy or hypersensitivity to blood products, blood-derived products, IVIg or immunoglobulin G (IgG) products
- •Patients who have immunoglobulin A (IgA) deficiency or anti-IgA antibody
- •Patients who are pregnant and nursing
- •Patients unwilling to use adequate method of contraception (hormonal methods, intrauterine device or intrauterine system, vasectomy, tubal ligation, etc.) during this study
- •Patients who had received other investigational products within 8 weeks from complete consent or who are scheduled to receive other investigational products during this study
- •Others whom the investigator considers ineligible for the study.
结局指标
主要结局
Rate of biliary complications
时间窗: 48 weeks
The number and rate of subjects with biliary complications including cholangitis, biliary leaks or biliary strictures for 48 weeks after liver transplantation (Experimental group vs. Comparator group)
次要结局
- Rate of transplant rejection(48 weeks)
- Rate of Donor Specific Antibody (DSA)(48 weeks)
- Rate of antibody reaction by ABO subtype(48 weeks)
- Rate of Cytomegalovirus (CMV) infection(48 weeks)
- Rate of infectious complications(48 weeks)
- Rate of Diffuse Intrahepatic Biliary Stricture (DIHBS)(48 weeks)
- Recurrence rate of Hepatocellular Carcinoma (HCC)(48 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT03164915SK Plasma Co., Ltd.37
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT05566990SK Plasma Co., Ltd.34
已完成
3 期
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyRheumatoid ArthritisNCT00361335Centocor, Inc.643
已完成
3 期
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyArthritis, RheumatoidNCT00973479Centocor, Inc.592
终止
3 期
IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke OnsetIschemic StrokeNCT01874093BrainsGate27